Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study: Study design and rationale

Christopher S. Almond, Holger Buchholz, Patricia Massicotte, Rebecca Ichord, David N. Rosenthal, Karen Uzark, Robert D B Jaquiss, Robert Kroslowitz, Mary Beth Kepler, Aaron Lobbestael, David Bellinger, Elizabeth D. Blume, Charles D. Fraser, Robert H. Bartlett, Ravi Thiagarajan, Kathy Jenkins

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background: Currently, there are no Food and Drug Administration-approved devices available that can provide long-term mechanical circulatory support to smaller children with severe heart failure as a bridge to heart transplant (HT). In recent years, the Berlin Heart EXCOR Pediatric ventricular assist device (VAD) has emerged as a potential treatment option. Systematic data on the safety and efficacy of the EXCOR are limited. Methods: The Investigational Device Exemption (IDE) clinical study is designed to evaluate the safety and probable benefit of the EXCOR to support regulatory review of the device under the Humanitarian Device Exemption regulation. The study design and rationale are reviewed in light of the well-described challenges inherent in small population studies. Results: The Berlin Heart EXCOR IDE clinical study is a prospective, multicenter, single-arm, clinical cohort study. Children aged 0 to 16 years with severe heart failure (Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2) due to 2-ventricle heart disease and actively listed for HT comprise the primary study cohort. The control population is a propensity-matched retrospective cohort of children supported with extracorporeal membrane oxygenation, the only bridge device available to smaller children before the EXCOR. The primary efficacy end point is survival to heart transplantation or recovery. The primary safety end point is the incidence of serious adverse events as defined by pediatric Interagency Registry for Mechanically Assisted Circulatory Support criteria. The study will enroll a total of 48 subjects in 2 cohorts based on body surface area (cohort 1 <0.7 m2, cohort 2 0.7-1.5 m2) and is powered to show safety superiority to a prespecified performance goal of 0.25 serious adverse events per day of support. Children ineligible for the primary cohort will still have access to the device in a third compassionate-use cohort where adverse event data will be collected for additional safety characterization of the device. Conclusion: The Berlin Heart IDE clinical study will be the first bridge-to-HT VAD study designed exclusively for children. It is anticipated that the study will provide important information on the safety and efficacy of the Berlin Heart EXCOR Pediatric in children while providing valuable lessons into the design and conduct of future VAD studies in children.

Original languageEnglish (US)
JournalAmerican Heart Journal
Volume162
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

Heart-Assist Devices
Berlin
Pediatrics
Equipment and Supplies
Safety
Compassionate Use Trials
Transplants
Registries
Cohort Studies
Heart Failure
Protective Devices
Extracorporeal Membrane Oxygenation
Body Surface Area
United States Food and Drug Administration
Heart Transplantation
Population
Heart Diseases
Clinical Studies
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study : Study design and rationale. / Almond, Christopher S.; Buchholz, Holger; Massicotte, Patricia; Ichord, Rebecca; Rosenthal, David N.; Uzark, Karen; Jaquiss, Robert D B; Kroslowitz, Robert; Kepler, Mary Beth; Lobbestael, Aaron; Bellinger, David; Blume, Elizabeth D.; Fraser, Charles D.; Bartlett, Robert H.; Thiagarajan, Ravi; Jenkins, Kathy.

In: American Heart Journal, Vol. 162, No. 3, 01.09.2011.

Research output: Contribution to journalArticle

Almond, CS, Buchholz, H, Massicotte, P, Ichord, R, Rosenthal, DN, Uzark, K, Jaquiss, RDB, Kroslowitz, R, Kepler, MB, Lobbestael, A, Bellinger, D, Blume, ED, Fraser, CD, Bartlett, RH, Thiagarajan, R & Jenkins, K 2011, 'Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study: Study design and rationale', American Heart Journal, vol. 162, no. 3. https://doi.org/10.1016/j.ahj.2011.05.026
Almond, Christopher S. ; Buchholz, Holger ; Massicotte, Patricia ; Ichord, Rebecca ; Rosenthal, David N. ; Uzark, Karen ; Jaquiss, Robert D B ; Kroslowitz, Robert ; Kepler, Mary Beth ; Lobbestael, Aaron ; Bellinger, David ; Blume, Elizabeth D. ; Fraser, Charles D. ; Bartlett, Robert H. ; Thiagarajan, Ravi ; Jenkins, Kathy. / Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study : Study design and rationale. In: American Heart Journal. 2011 ; Vol. 162, No. 3.
@article{36d2e7badff847fd9e9174de9f9cd98a,
title = "Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study: Study design and rationale",
abstract = "Background: Currently, there are no Food and Drug Administration-approved devices available that can provide long-term mechanical circulatory support to smaller children with severe heart failure as a bridge to heart transplant (HT). In recent years, the Berlin Heart EXCOR Pediatric ventricular assist device (VAD) has emerged as a potential treatment option. Systematic data on the safety and efficacy of the EXCOR are limited. Methods: The Investigational Device Exemption (IDE) clinical study is designed to evaluate the safety and probable benefit of the EXCOR to support regulatory review of the device under the Humanitarian Device Exemption regulation. The study design and rationale are reviewed in light of the well-described challenges inherent in small population studies. Results: The Berlin Heart EXCOR IDE clinical study is a prospective, multicenter, single-arm, clinical cohort study. Children aged 0 to 16 years with severe heart failure (Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2) due to 2-ventricle heart disease and actively listed for HT comprise the primary study cohort. The control population is a propensity-matched retrospective cohort of children supported with extracorporeal membrane oxygenation, the only bridge device available to smaller children before the EXCOR. The primary efficacy end point is survival to heart transplantation or recovery. The primary safety end point is the incidence of serious adverse events as defined by pediatric Interagency Registry for Mechanically Assisted Circulatory Support criteria. The study will enroll a total of 48 subjects in 2 cohorts based on body surface area (cohort 1 <0.7 m2, cohort 2 0.7-1.5 m2) and is powered to show safety superiority to a prespecified performance goal of 0.25 serious adverse events per day of support. Children ineligible for the primary cohort will still have access to the device in a third compassionate-use cohort where adverse event data will be collected for additional safety characterization of the device. Conclusion: The Berlin Heart IDE clinical study will be the first bridge-to-HT VAD study designed exclusively for children. It is anticipated that the study will provide important information on the safety and efficacy of the Berlin Heart EXCOR Pediatric in children while providing valuable lessons into the design and conduct of future VAD studies in children.",
author = "Almond, {Christopher S.} and Holger Buchholz and Patricia Massicotte and Rebecca Ichord and Rosenthal, {David N.} and Karen Uzark and Jaquiss, {Robert D B} and Robert Kroslowitz and Kepler, {Mary Beth} and Aaron Lobbestael and David Bellinger and Blume, {Elizabeth D.} and Fraser, {Charles D.} and Bartlett, {Robert H.} and Ravi Thiagarajan and Kathy Jenkins",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.ahj.2011.05.026",
language = "English (US)",
volume = "162",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study

T2 - Study design and rationale

AU - Almond, Christopher S.

AU - Buchholz, Holger

AU - Massicotte, Patricia

AU - Ichord, Rebecca

AU - Rosenthal, David N.

AU - Uzark, Karen

AU - Jaquiss, Robert D B

AU - Kroslowitz, Robert

AU - Kepler, Mary Beth

AU - Lobbestael, Aaron

AU - Bellinger, David

AU - Blume, Elizabeth D.

AU - Fraser, Charles D.

AU - Bartlett, Robert H.

AU - Thiagarajan, Ravi

AU - Jenkins, Kathy

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: Currently, there are no Food and Drug Administration-approved devices available that can provide long-term mechanical circulatory support to smaller children with severe heart failure as a bridge to heart transplant (HT). In recent years, the Berlin Heart EXCOR Pediatric ventricular assist device (VAD) has emerged as a potential treatment option. Systematic data on the safety and efficacy of the EXCOR are limited. Methods: The Investigational Device Exemption (IDE) clinical study is designed to evaluate the safety and probable benefit of the EXCOR to support regulatory review of the device under the Humanitarian Device Exemption regulation. The study design and rationale are reviewed in light of the well-described challenges inherent in small population studies. Results: The Berlin Heart EXCOR IDE clinical study is a prospective, multicenter, single-arm, clinical cohort study. Children aged 0 to 16 years with severe heart failure (Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2) due to 2-ventricle heart disease and actively listed for HT comprise the primary study cohort. The control population is a propensity-matched retrospective cohort of children supported with extracorporeal membrane oxygenation, the only bridge device available to smaller children before the EXCOR. The primary efficacy end point is survival to heart transplantation or recovery. The primary safety end point is the incidence of serious adverse events as defined by pediatric Interagency Registry for Mechanically Assisted Circulatory Support criteria. The study will enroll a total of 48 subjects in 2 cohorts based on body surface area (cohort 1 <0.7 m2, cohort 2 0.7-1.5 m2) and is powered to show safety superiority to a prespecified performance goal of 0.25 serious adverse events per day of support. Children ineligible for the primary cohort will still have access to the device in a third compassionate-use cohort where adverse event data will be collected for additional safety characterization of the device. Conclusion: The Berlin Heart IDE clinical study will be the first bridge-to-HT VAD study designed exclusively for children. It is anticipated that the study will provide important information on the safety and efficacy of the Berlin Heart EXCOR Pediatric in children while providing valuable lessons into the design and conduct of future VAD studies in children.

AB - Background: Currently, there are no Food and Drug Administration-approved devices available that can provide long-term mechanical circulatory support to smaller children with severe heart failure as a bridge to heart transplant (HT). In recent years, the Berlin Heart EXCOR Pediatric ventricular assist device (VAD) has emerged as a potential treatment option. Systematic data on the safety and efficacy of the EXCOR are limited. Methods: The Investigational Device Exemption (IDE) clinical study is designed to evaluate the safety and probable benefit of the EXCOR to support regulatory review of the device under the Humanitarian Device Exemption regulation. The study design and rationale are reviewed in light of the well-described challenges inherent in small population studies. Results: The Berlin Heart EXCOR IDE clinical study is a prospective, multicenter, single-arm, clinical cohort study. Children aged 0 to 16 years with severe heart failure (Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2) due to 2-ventricle heart disease and actively listed for HT comprise the primary study cohort. The control population is a propensity-matched retrospective cohort of children supported with extracorporeal membrane oxygenation, the only bridge device available to smaller children before the EXCOR. The primary efficacy end point is survival to heart transplantation or recovery. The primary safety end point is the incidence of serious adverse events as defined by pediatric Interagency Registry for Mechanically Assisted Circulatory Support criteria. The study will enroll a total of 48 subjects in 2 cohorts based on body surface area (cohort 1 <0.7 m2, cohort 2 0.7-1.5 m2) and is powered to show safety superiority to a prespecified performance goal of 0.25 serious adverse events per day of support. Children ineligible for the primary cohort will still have access to the device in a third compassionate-use cohort where adverse event data will be collected for additional safety characterization of the device. Conclusion: The Berlin Heart IDE clinical study will be the first bridge-to-HT VAD study designed exclusively for children. It is anticipated that the study will provide important information on the safety and efficacy of the Berlin Heart EXCOR Pediatric in children while providing valuable lessons into the design and conduct of future VAD studies in children.

UR - http://www.scopus.com/inward/record.url?scp=80052283184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052283184&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2011.05.026

DO - 10.1016/j.ahj.2011.05.026

M3 - Article

C2 - 21884857

AN - SCOPUS:80052283184

VL - 162

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -